Eva Segelov
Expertise in
4
conditions

Eva Segelov

St Vincent's Hospital, 
Darlinghurst, NSW, AU 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
4
conditions
St Vincent's Hospital, 
Darlinghurst, NSW, AU 

Overview

Eva Segelov practices in Darlinghurst, Australia. Ms. Segelov is highly rated in 4 conditions, according to our data. Her top areas of expertise are Colorectal Cancer, Anal Cancer, Neuroendocrine Tumor, and COVID-19.

Her clinical research consists of co-authoring 133 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender

Female

Locations

St Vincent's Hospital, Darlinghurst, NSW, Australia
Other Locations
St Vincent's Clinical School, 438 Victoria St, Darlinghurst, NSW 2010, Australia
St Vincent's Clinical School, Sydney, NSW 2052, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Statins and prOgression of Coronary atheRosclerosis in melanomA Patients Treated With chEckpoint inhibitorS
Statins and prOgression of Coronary atheRosclerosis in melanomA Patients Treated With chEckpoint inhibitorS
Enrollment Status: Recruiting
Publish Date: August 27, 2025
Study Drug: Atorvastatin Calcium
A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer
A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: April 04, 2025
Intervention Type: Drug
Study Drug: Fruquintinib
Study Phase: Phase 3
A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer
A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer
Enrollment Status: Terminated
Publish Date: November 14, 2023
Intervention Type: Drug
Study Drugs: Bintrafusp Alfa, Gemcitabine, Cisplatin
Study Phase: Phase 2/Phase 3
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
Enrollment Status: Completed
Publish Date: October 06, 2022
Intervention Type: Drug
Study Drugs: Avapritinib, Regorafenib
Study Phase: Phase 3
A Safety Study of Oraxol (HM30181 + Oral Paclitaxel) in Cancer Patients
A Safety Study of Oraxol (HM30181 + Oral Paclitaxel) in Cancer Patients
Enrollment Status: Completed
Publish Date: July 29, 2021
Intervention Type: Drug
Study Phase: Phase 2
An Open Label, Single Arm Pilot Study of OncoSil™, Administered to Study Participants With Unresectable Locally Advanced Pancreatic Adenocarcinoma, Given in Combination With FOLFIRINOX or Gemcitabine+Nab-paclitaxel Chemotherapies
An Open Label, Single Arm Pilot Study of OncoSil™, Administered to Study Participants With Unresectable Locally Advanced Pancreatic Adenocarcinoma, Given in Combination With FOLFIRINOX or Gemcitabine+Nab-paclitaxel Chemotherapies
Enrollment Status: Completed
Publish Date: July 13, 2021
Intervention Type: Device
Study Phase: Not Applicable
View 5 Less Clinical Trials

133 Total Publications

Target trial emulation: bridging observational studies and randomized trials for health decision-making.
Target trial emulation: bridging observational studies and randomized trials for health decision-making.
Journal: Journal of comparative effectiveness research
Published: March 19, 2026

Frequently Asked Questions about Eva Segelov

Is Eva Segelov a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Eva Segelov is classified as an Distinguished expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Eva Segelov participate in research or clinical trials?

Yes. Eva Segelov has published 133 articles and abstracts on conditions like Colorectal Cancer. You can view a list of Eva Segelov's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Segelov's expertise for a condition
ConditionClose
    View All 16 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile